MEP warns Big Tech could outpace healthcare regulation with AI, biofoundries

The chair of the European Parliament's health committee has cautioned that large technology companies are poised to transform healthcare at a pace current regulatory frameworks may not anticipate. Artificial intelligence and biofoundries were highlighted as primary drivers of this rapid change, underscoring an urgent need to re-evaluate existing pharmaceutical policy.

The European Union has initiated projects to address the complexities of AI integration in health. The Real4Reg project, for example, is developing AI-based data-driven methods and tools for assessing medicinal products, aiming to inform regulatory decision-making and health technology assessment across Europe. This initiative seeks to enable the use and establish the value of real-world evidence derived from real-world data, with findings intended to inform training activities and be implemented in guidelines for health regulatory authorities.

Further efforts include the AHEAD project, which focuses on creating a transdisciplinary community to develop standardised approaches for the responsible implementation of AI in biomedicine and healthcare. This project directly addresses the lack of consensus on ethical and trustworthy AI, particularly relevant in high-impact societal applications. Similarly, the AI4POL project is dedicated to supporting European regulators and policymakers by providing knowledge and tools to navigate the challenges and opportunities of ethical and trustworthy AI, acknowledging Europe's ambition to shape the future of global AI development through regulation. These projects collectively demonstrate an ongoing commitment to understanding and governing AI's role in health. However, the MEP's warning suggests the speed of technological advancement, particularly from large tech entities, may still outpace these significant regulatory developments.

What this means: Policymakers face increasing pressure to adapt regulatory frameworks quickly to keep pace with rapid technological advancements in healthcare driven by AI and biofoundries. The European Parliament's health committee chair's statement underscores the urgency of this challenge.